[go: up one dir, main page]

NO20015756L - Felles promedikamenter av amlodipin og atorvastatin - Google Patents

Felles promedikamenter av amlodipin og atorvastatin

Info

Publication number
NO20015756L
NO20015756L NO20015756A NO20015756A NO20015756L NO 20015756 L NO20015756 L NO 20015756L NO 20015756 A NO20015756 A NO 20015756A NO 20015756 A NO20015756 A NO 20015756A NO 20015756 L NO20015756 L NO 20015756L
Authority
NO
Norway
Prior art keywords
amlodipine
atorvastatin
drugs
compositions
mammal
Prior art date
Application number
NO20015756A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015756D0 (no
Inventor
George Chang
Ernest Seiichi Hamanaka
John Lawrence Lamattina
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20015756D0 publication Critical patent/NO20015756D0/no
Publication of NO20015756L publication Critical patent/NO20015756L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20015756A 1999-05-27 2001-11-26 Felles promedikamenter av amlodipin og atorvastatin NO20015756L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13660899P 1999-05-27 1999-05-27
PCT/IB2000/000313 WO2000073298A1 (fr) 1999-05-27 2000-03-20 Promedicaments communs d'amlodipine et d'atorvastatine

Publications (2)

Publication Number Publication Date
NO20015756D0 NO20015756D0 (no) 2001-11-26
NO20015756L true NO20015756L (no) 2002-01-24

Family

ID=22473579

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015756A NO20015756L (no) 1999-05-27 2001-11-26 Felles promedikamenter av amlodipin og atorvastatin

Country Status (41)

Country Link
US (1) US6486182B1 (fr)
EP (1) EP1180102B9 (fr)
JP (1) JP2003500487A (fr)
KR (1) KR20020012247A (fr)
CN (1) CN1352640A (fr)
AP (1) AP2001002345A0 (fr)
AR (1) AR022344A1 (fr)
AT (1) ATE268764T1 (fr)
AU (1) AU3313900A (fr)
BG (1) BG106149A (fr)
BR (1) BR0011006A (fr)
CA (1) CA2375372C (fr)
CO (1) CO5170457A1 (fr)
CZ (1) CZ20014229A3 (fr)
DE (1) DE60011424T2 (fr)
DK (1) DK1180102T3 (fr)
DZ (1) DZ3048A1 (fr)
EA (1) EA200101130A1 (fr)
EE (1) EE200100631A (fr)
ES (1) ES2220426T3 (fr)
GT (1) GT200000078A (fr)
HK (1) HK1046282A1 (fr)
HN (1) HN2000000075A (fr)
HR (1) HRP20010856A2 (fr)
HU (1) HUP0201433A2 (fr)
IL (1) IL145947A0 (fr)
IS (1) IS6135A (fr)
MA (1) MA26736A1 (fr)
MX (1) MXPA01012125A (fr)
NO (1) NO20015756L (fr)
OA (1) OA11950A (fr)
PA (1) PA8495701A1 (fr)
PE (1) PE20010169A1 (fr)
PL (1) PL353483A1 (fr)
PT (1) PT1180102E (fr)
SK (1) SK16792001A3 (fr)
SV (1) SV2002000082A (fr)
TN (1) TNSN00113A1 (fr)
TR (1) TR200103391T2 (fr)
WO (1) WO2000073298A1 (fr)
ZA (1) ZA200109691B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
KR20070108282A (ko) 2001-06-11 2007-11-08 제노포트 인코포레이티드 감소된 독성을 가진 ｇａｂａ 유사체 프로드러그의 구강투여용 투여 형태물
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
AU2005301970B2 (en) 2004-11-04 2011-06-02 Arbor Pharmaceuticals, Llc Gabapentin prodrug sustained release oral dosage forms
WO2007016306A2 (fr) * 2005-08-01 2007-02-08 Psivida Inc. Composes inhibiteurs de l'enzyme de conversion de l'angiotensine- inhibiteurs de la hmgcoa reductase
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US8371336B2 (en) 2007-10-10 2013-02-12 Eagle Industry Co., Ltd. Accumulator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
CO5170457A1 (es) 2002-06-27
CZ20014229A3 (cs) 2003-01-15
WO2000073298A1 (fr) 2000-12-07
SV2002000082A (es) 2002-02-05
HUP0201433A2 (en) 2002-08-28
TNSN00113A1 (fr) 2005-11-10
PL353483A1 (en) 2003-11-17
DE60011424D1 (de) 2004-07-15
MXPA01012125A (es) 2002-06-04
ATE268764T1 (de) 2004-06-15
HN2000000075A (es) 2001-02-02
BR0011006A (pt) 2002-02-19
PT1180102E (pt) 2004-08-31
TR200103391T2 (tr) 2002-04-22
EA200101130A1 (ru) 2002-04-25
ZA200109691B (en) 2002-11-26
JP2003500487A (ja) 2003-01-07
CN1352640A (zh) 2002-06-05
US6486182B1 (en) 2002-11-26
DK1180102T3 (da) 2004-09-06
CA2375372A1 (fr) 2000-12-07
IS6135A (is) 2001-10-30
DZ3048A1 (fr) 2004-03-27
IL145947A0 (en) 2002-07-25
AU3313900A (en) 2000-12-18
AP2001002345A0 (en) 2001-12-31
GT200000078A (es) 2001-11-16
EP1180102A1 (fr) 2002-02-20
CA2375372C (fr) 2007-01-09
OA11950A (en) 2006-04-13
EP1180102B9 (fr) 2005-03-02
AR022344A1 (es) 2002-09-04
HRP20010856A2 (en) 2002-12-31
DE60011424T2 (de) 2005-08-25
HK1046282A1 (zh) 2003-01-03
KR20020012247A (ko) 2002-02-15
EE200100631A (et) 2003-02-17
NO20015756D0 (no) 2001-11-26
BG106149A (en) 2002-05-31
ES2220426T3 (es) 2004-12-16
PA8495701A1 (es) 2001-12-14
EP1180102B1 (fr) 2004-06-09
SK16792001A3 (sk) 2003-03-04
MA26736A1 (fr) 2004-12-20
PE20010169A1 (es) 2001-02-10

Similar Documents

Publication Publication Date Title
NO20015756L (no) Felles promedikamenter av amlodipin og atorvastatin
BG106128A (en) Mutual salt of amlodipine and atorvastatin
TR200000561T2 (tr) Amlodipin ve atorvastatin içeren tedavisel bileşikler.
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
TR200000562T2 (tr) Amlodifin ve bir statin bileşiği içeren bileşim terapisi
DK0963200T3 (da) Præparater til inhibering af angiogenese omfattende thalidomid og et NSAID
HUS1200031I1 (hu) Dipeptidil peptidáz IV ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás elõállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
UY27402A1 (es) Composiciones farmacéuticas de amlodipina y atorvastatina
AU7001001A (en) Modified forms of pharmacologically active agents and uses therefor
DK1210119T3 (da) Farmaceutiske sammensætninger til oral og topisk administrering
DK1071463T3 (da) Fremgangsmåde og samensætninger ved anvendelse af terfenadinmetabolitter i kombination med leukotrieninhibitorer
ATE350064T1 (de) Pharmazeutische zusammensetzungen von rapamycines
ECSP003497A (es) Sal mutua de amlodipino y atorvastatina
UY26164A1 (es) Profarmácos mutuos de amlodipino y atorvastatina
CA2361288A1 (fr) Prodrogue commune de l'amlodipine et de l'atorvastatine
UY27187A1 (es) Composiciones farmacéuticas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application